14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Thu, 9 May 2024

Trading levels for AFMD

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.58 6.76 %
R2 5.44 3.98 %
R1 5.35 2.27 %
Current price: 5.23
Support S1 5.06 -3.29 %
S2 4.97 -5.00 %
S3 4.82 -7.78 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 6.44 23.14 %
R2 5.70 8.99 %
R1 5.29 1.15 %
Current price 5.23
Support S1 4.88 -6.69%
S2 4.79 -8.41%
S3 4.40 -15.87%

AFMD Predictions History

3 years ago
SHAMOO predicted that AFMD for 2021-04-12 is going

3 years ago
JS predicted that AFMD for 2021-01-14 is going $7.40 (-89.47%)

3 years ago
Regina Adams predicted that AFMD for 2020-06-23 is going

Rank:

5 years ago
NameNotImportant predicted that AFMD for 2019-05-06 is going $3.42 (-90.23%)

5 years ago
NameNotImportant predicted that AFMD for 2019-05-02 is going $3.24 (-90.47%)

5 years ago
NameNotImportant predicted that AFMD for 2019-04-29 is going $3.48 (-89.64%)

7 years ago
JWick199 predicted that AFMD for 2017-04-10 is going $2.64 (-88.77%)

Rank:

7 years ago
Augusto.Lorenzo.Milla.3918 predicted that AFMD for 2017-03-09 is going $2.32 (-90.13%)

Rank:

7 years ago
JS predicted that AFMD for 2017-03-06 is going $2.57 (-89.72%)

7 years ago
Krista.Endrich.3707 predicted that AFMD for 2017-03-06 is going $2.51 (-89.96%)

Rank:
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT